 |
HOME | CONTACT |
|
Nektar also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with a wide range of small to large organizations.
* Cimzia® is a registered trademark of UCB.
Longer-acting rFVIII and other therapeutic clotting proteins
Nektar and Baxter have two partnerships in hemophilia. Under the terms of the collaborations, Nektar is entitled to receive royalties on the global sales of rFVIII and other long-acting clotting protein programs for hemophilia that use Nektar's advanced polymer conjugate technologies. Nektar is also entitled to contract research and manufacturing revenues for these programs. Nektar's innovative releasable conjugate technology is used in the development of these therapeutics. The rFVIII "pro-drug concept", which is currently in preclinical development by Baxter with Nektar, is designed to create a new modified rFVIII with a significantly longer half life. Other therapeutics for hemophilia patients are also being studied in preclinical development with Baxter.
MAP0004™
Under the terms of a license agreement between Nektar and MAP Pharmaceuticals, Nektar is entitled to receive royalties on the global sales of MAP0004™ for all indications. MAP0004 is an orally inhaled version of dihydroergotamine (DHE), self-administered via MAP's proprietary Tempo® inhaler. DHE is available as an intravenous therapy which has been used in clinical settings for over 50 years to safely treat migraine. A Phase 3 program began in July 2008 for MAP0004.
Cipro Inhale
Under development by Bayer Healthcare, inhaled cipro is a targeted inhaled antibiotic therapy for pulmonary infections in cystic fibrosis patients. It is a specially formulated form of ciprofloxacin betaine that is delivered via dry powder inhalation to the target area of the lung. The investigational product candidate is currently in Phase 2 clinical trials in patients and features a small, hand-held inhaler for ease-of-use. Nektar is entitled to royalties on sales of Cipro Inhale upon commercialization.
NKTR-061
Amikacin Inhale combines a novel, preservative-free liquid formulation of antibiotic amikacin with a Liquid Pulmonary Technology (LPT™) originally developed by Nektar. The product is under development to treat Gram-negative pneumonias. 
NKTR-063
NKTR-063 (inhaled vancomycin) combines a Liquid Pulmonary Technology (LPT™) aerosol platform originally developed by Nektar with a specially formulated, highly concentrated, preservative free, lyophilized version of the antibiotic vancomycin.
Oral NKTR-118
Oral NKTR-118 is a novel peripheral opioid antagonist created using Nektar's advanced polymer conjugate technology.
Oral NKTR-119 (Oral NKTR-118 and opioid co-formulation product)
Oral NKTR-119 is an investigational drug candidate that is a co-formulation of Oral NKTR-118 and an opioid analgesic. The product is in preclinical stages for the treatment of analgesia without the gastrointestinal side effects associated with traditional opioid therapies.
NKTR-181
NKTR-181 is a potential abuse-deterrent and safer opioid designed using Nektar's advanced polymer conjugate technology platform. With regulated CNS entry, the opioid is designed to potentially have less euphoria associated with it, resulting in an abuse deterrent analgesic with reduced respiratory death. The stable opioid-polymer conjugate drug is also designed to be tamper-resistant.
NKTR-194
NKTR-194 is a potential non-scheduled opioid designed using Nektar's advanced polymer conjugate technology platform. The opioid is designed to be peripherally-acting without entry into the CNS. This potentially avoids the CNS side effects, gastrointestinal bleeding and cardiovascular risks associated with NSAIDs and COX-2 inhibitors used to treat moderate pain.
NKTR-171
NKTR-171 is a drug candidate designed to treat neuropathic pain without the CNS side effects. The product was developed using Nektar's advanced polymer conjugate technology and is in early research.
Cimzia®
Nektar technology is used in the antibody fragment, Cimzia® (certolizumab pegol). Cimzia® is the first and only PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody approved by the FDA for Crohn's disease. This product is approved in the U.S. and filed in the EU for rheumatoid arthritis and in phase 2 for psoriasis. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales of Cimzia® for all indications.
NKTR-125
Combines Nektar Advanced Polymer Conjugate technology with a potent anti-histamine to enhance its anti-inflammatory properties and minimize the undesirable side effects.
NKTR-140
NKTR-140 is a novel protease inhibitor created using Nektar's advanced polymer conjugate technology and is designed to have improved potency and eliminate the need for a co-administered protease inhibitor booster, such as ritonavir. NKTR-140 is in preclinical development and is expected to enter Phase 1 studies in Q4 2009.
NKTR-102
NKTR-102 is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile that provides a continuous concentration of active drug with reduced peak concentrations. NKTR-102 was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.
NKTR-105
NKTR-105 is a novel form of docetaxel created using Nektar's advanced polymer conjugate technology.
Hematide™
Nektar's proprietary conjugation technology is used in the novel peptide mimetic, Hematide™. The therapeutic is a synthetic, peptide-based erythropoiesis-stimulating agent under development by Takeda and Affymax. Under the terms of an exclusive agreement between Nektar and Affymax, Nektar is entitled to receive royalties on the global sales of Hematide™ for all indications, as well as manufacturing revenues. The product is currently in Phase 3 clinical trials for renal anemia.
CDP791
Nektar technology is used in the antibody fragment, CDP791. The product is in Phase 2 clinical trials for non-small cell lung cancer. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales of CDP791 for all indications. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide | Copyright Nektar © 2010 |